Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin.

Herroon MK, Rajagurubandara E, Diedrich JD, Heath EI, Podgorski I.

Sci Rep. 2018 Jan 8;8(1):40. doi: 10.1038/s41598-017-17800-5.

2.

Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.

Li A, Yadav R, White JK, Herroon MK, Callahan BP, Podgorski I, Turro C, Scott EE, Kodanko JJ.

Chem Commun (Camb). 2017 Mar 28;53(26):3673-3676. doi: 10.1039/c7cc01459g.

3.

Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1╬▒ activation.

Diedrich JD, Rajagurubandara E, Herroon MK, Mahapatra G, H├╝ttemann M, Podgorski I.

Oncotarget. 2016 Oct 4;7(40):64854-64877. doi: 10.18632/oncotarget.11712.

4.

New 3D-Culture Approaches to Study Interactions of Bone Marrow Adipocytes with Metastatic Prostate Cancer Cells.

Herroon MK, Diedrich JD, Podgorski I.

Front Endocrinol (Lausanne). 2016 Jul 6;7:84. doi: 10.3389/fendo.2016.00084. eCollection 2016.

5.

Photoactivated inhibition of cathepsin K in a 3D tumor model.

Herroon MK, Sharma R, Rajagurubandara E, Turro C, Kodanko JJ, Podgorski I.

Biol Chem. 2016 Jun 1;397(6):571-82. doi: 10.1515/hsz-2015-0274.

6.

Selective Release of Aromatic Heterocycles from Ruthenium Tris(2-pyridylmethyl)amine with Visible Light.

Li A, White JK, Arora K, Herroon MK, Martin PD, Schlegel HB, Podgorski I, Turro C, Kodanko JJ.

Inorg Chem. 2016 Jan 4;55(1):10-2. doi: 10.1021/acs.inorgchem.5b02600. Epub 2015 Dec 15.

7.

Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer.

Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I.

Clin Exp Metastasis. 2015 Apr;32(4):353-68. doi: 10.1007/s10585-015-9714-5. Epub 2015 Mar 24.

8.

Inhibition of cathepsin activity in a cell-based assay by a light-activated ruthenium compound.

Respondek T, Sharma R, Herroon MK, Garner RN, Knoll JD, Cueny E, Turro C, Podgorski I, Kodanko JJ.

ChemMedChem. 2014 Jun;9(6):1306-15. doi: 10.1002/cmdc.201400081. Epub 2014 Apr 11.

9.

Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.

Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I.

Cancer Metastasis Rev. 2014 Sep;33(2-3):527-43. doi: 10.1007/s10555-013-9484-y. Review.

10.

Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms.

Herroon MK, Rajagurubandara E, Hardaway AL, Powell K, Turchick A, Feldmann D, Podgorski I.

Oncotarget. 2013 Nov;4(11):2108-23.

11.

Macrophage cathepsin K promotes prostate tumor progression in bone.

Herroon MK, Rajagurubandara E, Rudy DL, Chalasani A, Hardaway AL, Podgorski I.

Oncogene. 2013 Mar 21;32(12):1580-93. doi: 10.1038/onc.2012.166. Epub 2012 May 21.

12.

Light activation of a cysteine protease inhibitor: caging of a peptidomimetic nitrile with Ru(II)(bpy)2.

Respondek T, Garner RN, Herroon MK, Podgorski I, Turro C, Kodanko JJ.

J Am Chem Soc. 2011 Nov 2;133(43):17164-7. doi: 10.1021/ja208084s. Epub 2011 Oct 12.

13.

Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.

Podgorski I, Linebaugh BE, Koblinski JE, Rudy DL, Herroon MK, Olive MB, Sloane BF.

Am J Pathol. 2009 Sep;175(3):1255-69. doi: 10.2353/ajpath.2009.080906. Epub 2009 Aug 21.

Supplemental Content

Loading ...
Support Center